Novo Nordisk
NVO
1,747 hedge funds and large institutions have $41.8B invested in Novo Nordisk in 2024 Q1 according to their latest regulatory filings, with 321 funds opening new positions, 730 increasing their positions, 484 reducing their positions, and 69 closing their positions.
365% more first-time investments, than exits
New positions opened: 321 | Existing positions closed: 69
51% more repeat investments, than reductions
Existing positions increased: 730 | Existing positions reduced: 484
30% more capital invested
Capital invested by funds: $32.2B → $41.8B (+$9.64B)
16% more funds holding
Funds holding: 1,512 → 1,747 (+235)
14% more funds holding in top 10
Funds holding in top 10: 70 → 80 (+10)
0.36% more ownership
Funds ownership: 6.93% → 7.29% (+0.36%)
10% less call options, than puts
Call options by funds: $1.01B | Put options by funds: $1.13B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$588M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$375M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$205M |
| 4 |
Morgan Stanley
New York
|
+$166M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$138M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$365M |
| 2 |
BlackRock
New York
|
-$206M |
| 3 |
Jennison Associates
New York
|
-$172M |
| 4 |
SFM
Soros Fund Management
New York
|
-$90.1M |
| 5 |
Millennium Management
New York
|
-$79.7M |
NVO Hedge Fund Activity: Q1 2024 in Review
1,747 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2024, worth a combined $41.8B — up 30% from $32.2B a quarter earlier.
Buyers outnumbered sellers: 321 funds opened new NVO positions and 69 closed out — a net gain of 252 holders — while 730 added to existing stakes and 484 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $588M. The largest seller was Renaissance Technologies, cutting an estimated $365M.
- 1,747 institutional investors held Novo Nordisk (NVO) as of Q1 2024, up from 1,512 in Q4 2023.
- Funds reported $41.8B of Novo Nordisk stock for Q1 2024, up 30% quarter-over-quarter.
- 321 funds opened new Novo Nordisk positions in Q1 2024 and 69 closed out, a net change of +252 holders.
- The largest Novo Nordisk buyer in Q1 2024 was Fidelity Investments, an estimated $588M added.
- The largest Novo Nordisk seller in Q1 2024 was Renaissance Technologies, an estimated $365M sold.
Based on aggregated 13F filings for Q1 2024.